M&As this week: Sun Pharmaceutical Industries, Northeast Pharmaceutical Group, Mallinckrodt


Sun Pharmaceutical Industries has announced the acquisition of a 15.91% stake in Krystal Biotech for $7m.

Both companies involved in the acquisition are based in India.

Chinese pharmaceutical company Northeast Pharmaceutical Group plans to acquire another pharmaceutical company based in China through its wholly owned subsidiary for CNY120m ($17.82m).

UK-based specialist pharmaceutical company Mallinckrodt plans to acquire US-based pharmaceutical company InfaCare Pharmaceutical Corporation for an initial upfront payment of $80m.

"Chinese pharmaceutical company Northeast Pharmaceutical Group plans to acquire another pharmaceutical company based in China through its wholly owned subsidiary for CNY120m ($17.82m)."

Mallinckrodt will make additional payments of up to $345m upon achieving regulatory and sales milestones.

The acquisition will enable Mallinckrodt to expand its paediatric product portfolio.

Formosa Laboratories plans to acquire Activus Pharma through its subsidiary Formosa Pharmaceuticals from Sosei Group Corporation.

Formosa is an active pharmaceutical ingredients (APIs) manufacturer based in Taiwan, while both Activus Pharma and Sosei Group Corporation are pharmaceutical companies based in Japan.